Ligand id: 2326

Name: riluzole

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 76.38
Molecular weight 234.01
XLogP 2.42
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of amyotrophic lateral sclerosis (ALS, a.k.a. motor neurone disease or MND).
Riluzole, along with amiloride and fluoxetine are repurposing candidates as potential therapeutics for secondary progressive multiple sclerosis (SPMS or late MS), having already been shown to provide neuroprotective benefit [2,5-7]. A Phase 2 clinical trial in secondary progressive MS (NCT01910259, MS-SMART trial) is ongoing (Jan 2018).
Mechanism Of Action and Pharmacodynamic Effects
The mechanism of action of riluzole is complex, and appears to include inhibition of glutamate release, inactivation of voltage-dependent sodium channels and interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. Due to the complex nature of this drug's MMOA, we do not tag a primary drug target.
External links